1087 related articles for article (PubMed ID: 11929080)
21. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
23. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
[TBL] [Abstract][Full Text] [Related]
24. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer.
Zhang HS; Wang RJ; Fu QF; Gao S; Sun BT; Sun H; Ma QJ
Asian Pac J Cancer Prev; 2014; 15(24):10905-9. PubMed ID: 25605199
[TBL] [Abstract][Full Text] [Related]
26. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
27. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
28. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
[TBL] [Abstract][Full Text] [Related]
29. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
31. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
[TBL] [Abstract][Full Text] [Related]
32. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
Liu L; Huang F; Liu B; Huang R
J Pediatr Endocrinol Metab; 2018 Jul; 31(7):751-756. PubMed ID: 29953410
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
34. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
35. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
[TBL] [Abstract][Full Text] [Related]
37. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
39. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
